See more : EVANS ELECTRIC LIMITED (EVANS.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Xtant Medical Holdings, Inc. (XTNT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Xtant Medical Holdings, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
- AF Acquisition Corp. (AFAQW) Income Statement Analysis – Financial Results
- Medcolcanna Organics Inc. (MCCNF) Income Statement Analysis – Financial Results
- Harvest Technology Group Limited (HTG.AX) Income Statement Analysis – Financial Results
- Red Pine Exploration Inc. (RPX.V) Income Statement Analysis – Financial Results
- Founder Securities Co., Ltd. (601901.SS) Income Statement Analysis – Financial Results
Xtant Medical Holdings, Inc. (XTNT)
About Xtant Medical Holdings, Inc.
Xtant Medical Holdings, Inc. develops, manufactures, and markets regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally. Its biomaterial products include OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSponge SC that fills bony defects in the subchondral region of joints; OsteoSelect DBM Putty for osteoinductive bone growth; OsteoSelect PLUS DBM Putty for use as a bone void filler and bone graft substitute in the pelvis, extremities, and posterolateral spine; OsteoFactor, which contains various proteins and peptides that support bone formation and remodeling; OsteoWrap; and OsteoVive Plus, a growth factor enriched cellular bone matrix. The company also provides 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone. In addition, it processes and distributes sports allografts for anterior and posterior cruciate ligament repairs, anterior cruciate ligament reconstruction, and meniscal repair; milled spinal allografts for cortical bone milled to desired shapes and dimensions; and traditional allografts for orthopedics, neurology, podiatry, oral/maxillofacial, genitourinary, and plastic/reconstructive applications. Further, the company offers Certex spinal fixation, Spider cervical plating, Axle interspinous fusion, Silex Sacroiliac joint fusion, Xpress minimally invasive pedicle screw, and Fortex Pedicle screw systems. Additionally, it provides Calix for cervical and thoracolumbar applications, Axle-X interspinous fusion system, Irix-C cervical integrated fusion system, and Irix-A Lumbar integrated fusion system. The company was formerly known as Bacterin International Holdings, Inc. and changed its name to Xtant Medical Holdings, Inc. in July 2015. Xtant Medical Holdings, Inc. is headquartered in Belgrade, Montana.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 91.30M | 57.97M | 55.26M | 53.34M | 64.68M | 72.20M | 82.61M | 90.00M | 59.35M | 35.33M | 33.07M | 32.98M | 30.15M | 15.42M | 7.39M | 459.23K |
| Cost of Revenue | 35.84M | 25.83M | 22.77M | 18.95M | 22.17M | 28.72M | 32.51M | 27.71M | 20.26M | 13.03M | 14.19M | 10.34M | 9.11M | 3.36M | 2.32M | 386.48K |
| Gross Profit | 55.47M | 32.14M | 32.49M | 34.39M | 42.52M | 43.49M | 50.10M | 62.29M | 39.08M | 22.30M | 18.89M | 22.64M | 21.04M | 12.05M | 5.08M | 72.75K |
| Gross Profit Ratio | 60.75% | 55.44% | 58.79% | 64.48% | 65.73% | 60.23% | 60.65% | 69.21% | 65.86% | 63.11% | 57.11% | 68.66% | 69.79% | 78.18% | 68.65% | 15.84% |
| Research & Development | 1.34M | 915.00K | 870.00K | 657.00K | 932.00K | 1.70M | 2.44M | 3.41M | 2.55M | 1.44M | 572.36K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 25.85M | 15.46M | 14.45M | 13.50M | 17.94M | 13.00M | 15.33M | 16.03M | 13.24M | 9.02M | 10.77M | 11.56M | 8.23M | 11.14M | 0.00 | 0.00 |
| Selling & Marketing | 38.44M | 22.52M | 21.03M | 20.98M | 25.84M | 32.06M | 40.51M | 44.06M | 28.73M | 16.91M | 16.02M | 15.62M | 18.50M | 8.90M | 0.00 | 0.00 |
| SG&A | 64.29M | 37.98M | 35.47M | 34.49M | 43.78M | 45.06M | 55.84M | 60.09M | 41.97M | 25.93M | 26.79M | 27.18M | 26.74M | 20.03M | 4.16M | 88.59K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 58.00K | 3.00K | -74.71K | -351.91K | 388.18K | -318.84K | 92.65K | -1.56M | 755.39K | 633.83K | 72.30K | 88.59K |
| Operating Expenses | 65.63M | 38.89M | 36.34M | 35.14M | 44.77M | 50.88M | 63.77M | 68.44M | 48.34M | 27.65M | 27.17M | 27.59M | 27.49M | 20.67M | 8.70M | 88.59K |
| Cost & Expenses | 101.46M | 64.72M | 59.12M | 54.09M | 66.94M | 79.60M | 96.28M | 96.15M | 68.60M | 40.68M | 41.35M | 37.92M | 36.60M | 24.03M | 11.02M | 475.07K |
| Interest Income | 149.00K | 31.00K | 995.00K | 5.98M | 5.77M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.04K | 12.99K | 0.00 |
| Interest Expense | 2.94M | 1.69M | 995.00K | 5.98M | 5.77M | 10.15M | 14.70M | 12.26M | 7.73M | 5.66M | 4.65M | 1.86M | 1.16M | 1.65M | 513.93K | 0.00 |
| Depreciation & Amortization | 3.17M | 1.30M | 1.34M | 2.10M | 3.20M | 5.74M | 8.39M | 7.24M | 4.89M | 952.32K | 377.52K | 782.89K | 755.39K | 682.54K | 707.93K | 0.00 |
| EBITDA | 5.07M | -5.43M | -2.51M | 1.33M | 850.00K | -54.22M | -29.31M | 61.43K | -7.09M | -3.90M | -7.29M | -5.07M | -1.09M | -17.14M | -2.90M | -15.85K |
| EBITDA Ratio | 5.56% | -9.37% | -4.56% | 2.49% | 1.22% | -1.11% | -6.46% | 0.83% | -6.70% | -13.36% | -23.61% | -19.49% | -18.89% | -51.44% | -39.28% | -3.45% |
| Operating Income | -10.16M | -6.76M | -3.85M | -751.00K | -2.35M | -60.08M | -37.83M | -7.55M | -12.08M | -6.26M | -9.01M | -4.94M | -6.45M | -8.61M | -3.62M | -15.85K |
| Operating Income Ratio | -11.13% | -11.65% | -6.97% | -1.41% | -3.64% | -83.21% | -45.80% | -8.38% | -20.35% | -17.73% | -27.24% | -14.99% | -21.39% | -55.87% | -49.00% | -3.45% |
| Total Other Income/Expenses | 9.12M | -1.66M | -995.00K | -5.98M | -5.87M | -10.02M | -14.58M | -11.90M | -7.63M | -4.24M | -3.69M | -2.77M | 3.44M | -10.85M | 3.63M | 0.00 |
| Income Before Tax | -1.04M | -8.42M | -4.85M | -6.73M | -8.12M | -70.10M | -52.41M | -19.44M | -19.71M | -10.51M | -12.69M | -7.71M | -3.01M | -19.47M | -4.13M | -15.85K |
| Income Before Tax Ratio | -1.14% | -14.52% | -8.77% | -12.61% | -12.56% | -97.09% | -63.44% | -21.60% | -33.22% | -29.74% | -38.38% | -23.39% | -9.97% | -126.27% | -55.80% | -3.45% |
| Income Tax Expense | -1.70M | 69.00K | 995.00K | 296.00K | 98.00K | 124.00K | 14.63M | 50.36K | -17.54M | 5.34M | 4.75M | 306.26K | 1.16M | 1.65M | 1.83K | 0.00 |
| Net Income | 660.00K | -8.49M | -5.84M | -7.02M | -8.22M | -70.10M | -52.41M | -19.49M | -2.17M | -10.51M | -12.69M | -7.71M | -3.01M | -19.47M | -4.13M | -15.85K |
| Net Income Ratio | 0.72% | -14.64% | -10.57% | -13.17% | -12.71% | -97.09% | -63.44% | -21.66% | -3.66% | -29.74% | -38.38% | -23.39% | -9.97% | -126.27% | -55.80% | -3.45% |
| EPS | 0.01 | -0.09 | -0.07 | -0.25 | -0.62 | -5.97 | -34.76 | -18.46 | -2.62 | -19.26 | -29.15 | -19.83 | -8.43 | -66.03 | -17.02 | -0.07 |
| EPS Diluted | 0.01 | -0.09 | -0.07 | -0.25 | -0.62 | -5.93 | -34.51 | -18.32 | -2.62 | -19.26 | -29.15 | -19.83 | -8.43 | -66.03 | -17.02 | -0.07 |
| Weighted Avg Shares Out | 119.09M | 94.09M | 85.46M | 28.50M | 13.16M | 11.74M | 1.51M | 1.06M | 829.71K | 545.55K | 435.49K | 388.91K | 356.83K | 294.83K | 242.40K | 242.40K |
| Weighted Avg Shares Out (Dil) | 126.79M | 94.09M | 85.46M | 28.50M | 13.16M | 11.83M | 1.52M | 1.06M | 829.71K | 545.55K | 435.49K | 388.91K | 356.83K | 294.83K | 242.40K | 242.40K |
Xtant Medical Reports Second Quarter 2024 Revenue Growth of 48%
Xtant Medical to Present at the Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase
Xtant Medical Holdings, Inc. (XTNT) Q1 2024 Earnings Call Transcript
Xtant Medical Reports First Quarter 2024 Revenue Growth of 55% and Raises Full Year 2024 Revenue Guidance
Xtant Medical to Issue First Quarter 2024 Financial Results on May 15, 2024
Xtant Medical Announces Launch of SimpliGraft™ and SimpliMax™ for Chronic and Acute Wounds
Xtant Medical Holdings Inc. (XTNT) Q4 2023 Earnings Call Transcript
Xtant Medical Announces Record Full Year 2023 Revenue of $91.3 Million
Xtant Medical to Issue Fourth Quarter and Full Year 2023 Financial Results on April 1, 2024
Xtant Medical Increases Revolving Credit Facility to $17 Million with MidCap Financial
Source: https://incomestatements.info
Category: Stock Reports
What were the key drivers of Xtant Medical’s revenue growth in 2024?
The increase is primarily due to the contribution of additional sales resulting from the acquisition of the Surgalign Holdings’ hardware and biologics business, greater independent agent sales and additional Coflex and CoFix product sales.
How did Xtant Medical’s gross margin change in Q3 2024?
Gross margin for the third quarter of 2024 was 58.4%, compared to 61.3% for the prior year quarter. The decrease is primarily due to reduced production throughput, partially offset by additional scale.